Vixarelimab
- Generic Name
- Vixarelimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2243320-83-2
- Unique Ingredient Identifier
- W25GO3A75W
- Background
Vixarelimab is under investigation in clinical trial NCT03816891 (A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Prurigo Nodularis).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06693908
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT06137183
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇩🇪Universitaetsklinikum Halle (Saale); Universitatsklinik und Poliklinik fur Innere Medizin I, Halle, Germany
🇵🇱PlanetMed, Wroc?aw, Poland
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
- Conditions
- Interventions
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT05785624
- Locations
- 🇲🇽
Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Southern Arizona VA Health Care System NAVREF PPDS, Tucson, Arizona, United States
Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Kiniksa Pharmaceuticals, Ltd.
- Target Recruit Count
- 190
- Registration Number
- NCT03816891
- Locations
- 🇧🇪
Site 2701, Liège, Belgium
🇩🇪Site 2011, Dresden, Germany
🇩🇪Site 2008, Göttingen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.